Eli Lilly's Olumiant (baricitinib) Receives FDA Approval for Moderately-to-Severely Active Rheumatoid Arthritis (RA) in Adults
Shots:
- The approval is based on P-III RA-BEACON study results assessing Olumiant vs PBO in 527 patients with inadequate response or intolerance to one or more TNF inhibitor therapies
- P-III RA-BEACON study results: ACR20 (49% vs 27%) physical function based on the Health Assessment Questionnaire Disability Index (HAQ-DI) before/ after treatment (1.71- 1.78/ 1.31- 1.59)
- Olumiant (baricitinib- 2mg) is an oral drug indicated for patients with RA who have inadequate response to TNF antagonist therapies and is approved in 50 countries including the US- EU and Japan. In Dec-2009 Lilly and Incyte collaborated to develop and commercialize Olumiant for inflammatory and autoimmune diseases
Ref: Eli Lilly | Image: Eli Lilly
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com